Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Phase 2 KEYNOTE-087 study Meeting Abstract
| Authors: | Chen, R. W.; Zinzani, P. L.; Fanale, M. A.; Armand, P.; Johnson, N.; Ribrag, V.; Radford, J. A.; Tomita, A.; Shipp, M. A.; Wang, Y.; Ricart, A. D.; Balakumaran, A.; Moskowitz, C. H. |
| Abstract Title: | Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Phase 2 KEYNOTE-087 study |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 408s |
| Language: | English |
| ACCESSION: | WOS:000404711505068 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.7555 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7555 -- Source: Wos |
